Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

560 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
van Kesteren C, Twelves C, Bowman A, Hoekman K, López-Lázaro L, Jimeno J, Guzman C, Mathôt RA, Simpson A, Vermorken JB, Smyth J, Schellens JH, Hillebrand MJ, Rosing H, Beijnen JH. van Kesteren C, et al. Among authors: vermorken jb. Anticancer Drugs. 2002 Apr;13(4):381-93. doi: 10.1097/00001813-200204000-00007. Anticancer Drugs. 2002. PMID: 11984084 Clinical Trial.
Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction.
Rosing H, Hillebrand MJ, Jimeno JM, Gómez A, Floriano P, Faircloth G, Cameron L, Henrar RE, Vermorken JB, Bult A, Beijnen JH. Rosing H, et al. Among authors: vermorken jb. J Chromatogr B Biomed Sci Appl. 1998 Jun 12;710(1-2):183-9. doi: 10.1016/s0378-4347(98)00143-1. J Chromatogr B Biomed Sci Appl. 1998. PMID: 9686886
Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Rosing H, Hillebrand MJ, Jimeno JM, Gómez A, Floriano P, Faircloth G, Henrar RE, Vermorken JB, Cvitkovic E, Bult A, Beijnen JH. Rosing H, et al. Among authors: vermorken jb. J Mass Spectrom. 1998 Nov;33(11):1134-40. doi: 10.1002/(SICI)1096-9888(1998110)33:11<1134::AID-JMS730>3.0.CO;2-S. J Mass Spectrom. 1998. PMID: 9835068 Clinical Trial.
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C, Hoekman K, Bowman A, Vermorken JB, Anthoney A, Smyth J, van Kesteren C, Beijnen JH, Uiters J, Wanders J, Gomez J, Guzmán C, Jimeno J, Hanauske A. Twelves C, et al. Among authors: vermorken jb. Eur J Cancer. 2003 Sep;39(13):1842-51. doi: 10.1016/s0959-8049(03)00458-1. Eur J Cancer. 2003. PMID: 12932661 Clinical Trial.
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH; EORTC-PAMM-NDDG. Joerger M, et al. Among authors: vermorken jb. Clin Pharmacokinet. 2007;46(12):1051-68. doi: 10.2165/00003088-200746120-00005. Clin Pharmacokinet. 2007. PMID: 18027989 Clinical Trial.
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Panday VR, ten Bokkel Huinink WW, Vermorken JB, Rosing H, Koopman FJ, Swart M, Schellens JH, Beijnen JH. Panday VR, et al. Among authors: vermorken jb. Pharmacol Res. 1999 Jul;40(1):67-74. doi: 10.1006/phrs.1999.0477. Pharmacol Res. 1999. PMID: 10378993 Clinical Trial.
560 results